Compare Stocks: ONCY, EBS, ELYM, and OCGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent Biosolutions	$6.33 -0.7%	$6.11	$4.36 ▼ $14.06	$324.56M	2.28	1.07 million shs	614,534 shs
ELYM Eliem Therapeutics	$10.94 -1.2%	$14.16	$2.35 ▼ $11.55	$325.49M	-0.39	486,688 shs	1.58 million shs
OCGN Ocugen	$1.02 +2.0%	$1.22	$0.97 ▼ $2.73	$345.89M	2.27	9.13 million shs	3.29 million shs
ONCY Oncolytics Biotech	$0.63 -1.6%	$0.78	$0.62 ▼ $1.42	$80.46M	1.15	1.09 million shs	609,209 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent Biosolutions	0.00%	-6.92%	+1.52%	-23.66%	-31.06%
ELYM Eliem Therapeutics	-1.17%	-6.17%	-27.31%	-15.19%	+444.28%
OCGN Ocugen	0.00%	0.00%	-24.44%	-32.45%	-39.29%
ONCY Oncolytics Biotech	0.00%	-7.65%	-26.33%	-29.82%	-55.56%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent Biosolutions	$6.33 -0.7%	$6.11	$4.36 ▼ $14.06	$324.56M	2.28	1.07 million shs	614,534 shs
ELYM Eliem Therapeutics	$10.94 -1.2%	$14.16	$2.35 ▼ $11.55	$325.49M	-0.39	486,688 shs	1.58 million shs
OCGN Ocugen	$1.02 +2.0%	$1.22	$0.97 ▼ $2.73	$345.89M	2.27	9.13 million shs	3.29 million shs
ONCY Oncolytics Biotech	$0.63 -1.6%	$0.78	$0.62 ▼ $1.42	$80.46M	1.15	1.09 million shs	609,209 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent Biosolutions	0.00%	-6.92%	+1.52%	-23.66%	-31.06%
ELYM Eliem Therapeutics	-1.17%	-6.17%	-27.31%	-15.19%	+444.28%
OCGN Ocugen	0.00%	0.00%	-24.44%	-32.45%	-39.29%
ONCY Oncolytics Biotech	0.00%	-7.65%	-26.33%	-29.82%	-55.56%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EBS Emergent Biosolutions	2.17	Hold	$10.00	58.10% Upside
ELYM Eliem Therapeutics	0.00	N/A	N/A	N/A
OCGN Ocugen	2.60	Moderate Buy	$9.50	831.37% Upside
ONCY Oncolytics Biotech	2.67	Moderate Buy	$5.00	692.39% Upside

Current Analyst Ratings Breakdown

Latest ONCY, EBS, ELYM, and OCGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	EBS Emergent Biosolutions	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
8/21/2026	EBS Emergent Biosolutions	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
8/21/2026	EBS Emergent Biosolutions	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Underweight
8/19/2026	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00
8/11/2026	OCGN Ocugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	EBS Emergent Biosolutions	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/10/2026	EBS Emergent Biosolutions	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$12.00 ➝ $10.00
8/7/2026	EBS Emergent Biosolutions	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/13/2026	ONCY Oncolytics Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EBS Emergent Biosolutions	$742.90M	0.44	$3.66 per share	1.73	$9.95 per share	0.64
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	$3.90 per share	N/A
OCGN Ocugen	$4.41M	78.43	N/A	N/A	($0.04) per share	-25.50
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	($0.04) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EBS Emergent Biosolutions	$52.60M	-$3.55	N/A	8.55	N/A	-22.95%	16.35%	6.17%	11/4/2026 (Estimated)
ELYM Eliem Therapeutics	-$35.12M	-$0.53	N/A	N/A	N/A	N/A	-47.03%	-45.97%	N/A
OCGN Ocugen	-$67.85M	-$0.26	N/A	N/A	N/A	N/A	-127,987.80%	-115.95%	11/4/2026 (Estimated)
ONCY Oncolytics Biotech	-$28.76M	-$0.34	N/A	N/A	N/A	N/A	N/A	-442.99%	11/11/2026 (Estimated)

Latest ONCY, EBS, ELYM, and OCGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ONCY Oncolytics Biotech	-$0.0538	-$0.08	-$0.0262	-$0.08	N/A	N/A
8/6/2026	Q2 2026	OCGN Ocugen	-$0.0533	-$0.07	-$0.0167	-$0.07	$0.89 million	$1.49 million
8/5/2026	Q2 2026	EBS Emergent Biosolutions	-$0.0850	$0.60	+$0.6850	-$3.49	$177.50 million	$234.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EBS Emergent Biosolutions	1.70	5.42	2.95
ELYM Eliem Therapeutics	N/A	60.41	60.41
OCGN Ocugen	4.17	0.80	0.80
ONCY Oncolytics Biotech	N/A	1.35	1.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EBS Emergent Biosolutions	78.40%
ELYM Eliem Therapeutics	69.76%
OCGN Ocugen	10.27%
ONCY Oncolytics Biotech	6.82%

Insider Ownership

Company	Insider Ownership
EBS Emergent Biosolutions	6.00%
ELYM Eliem Therapeutics	4.70%
OCGN Ocugen	3.95%
ONCY Oncolytics Biotech	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EBS Emergent Biosolutions	900	51.27 million	48.20 million	Optionable
ELYM Eliem Therapeutics	9	29.75 million	28.35 million	Not Optionable
OCGN Ocugen	116	339.11 million	325.72 million	Optionable
ONCY Oncolytics Biotech	29	127.51 million	127.38 million	Not Optionable

ONCY, EBS, ELYM, and OCGN Headlines

Recent News About These Companies

Oncolytics Highlights Pelareorep Preclinical Findings In Hepatocellular Carcinoma

September 30, 2026 | rttnews.com

Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy

September 29, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY) and Spyre Therapeutics (SYRE)

September 28, 2026 | theglobeandmail.com

Oncolytics Nears Interim Data Update From Randomized REO 033 Colorectal Cancer Study

September 28, 2026 | rttnews.com

Oncolytics Biotech Announces Progress in REO 033 Trial, Site Activations and FDA-Aligned Pathway for Pelareorep in Metastatic Colorectal Cancer

September 28, 2026 | quiverquant.comQ

Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study

September 28, 2026 | globenewswire.com

Oncolytics Biotech (NASDAQ:ONCY) Trading Down 5.2% - Time to Sell?

September 23, 2026 | marketbeat.com

Oncolytics Biotech, Inc.: Oncolytics Biotech Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer

September 10, 2026 | finanznachrichten.de

Oncolytics Biotech Reports Preclinical Pelareorep Activity Maintained with RAS Inhibition

September 10, 2026 | quiverquant.comQ

Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer

September 10, 2026 | globenewswire.com

Oncolytics Biotech gains FDA alignment on REO 033 trial

August 20, 2026 | theglobeandmail.com

Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer

August 18, 2026 | globenewswire.com

Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer

July 20, 2026 | globenewswire.com

ONCY: Seeking Registration Pathway for Part B of REO 033 Trial

July 16, 2026 | finance.yahoo.com

Oncolytics Biotech Announces Rapid REO 033 Site Activation and FDA Meeting on Registrational Pathway for Pelareorep in Metastatic Colorectal Cancer

July 13, 2026 | quiverquant.comQ

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial

July 13, 2026 | globenewswire.com

Oncolytics Biotech Secures New Pelareorep Manufacturing Patent

June 16, 2026 | tipranks.com

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

June 16, 2026 | globenewswire.com

Oncolytics Biotech (ONCY) Valuation Check As New Pelareorep RAS Combo Data Draws Investor Attention

June 5, 2026 | finance.yahoo.com

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer

June 2, 2026 | globenewswire.com

ONCY stock heads for sixth straight session of gains – lead therapy shines in early combination treatment study

June 1, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY, EBS, ELYM, and OCGN Company Descriptions

Emergent Biosolutions NYSE:EBS

$6.32 -0.05 (-0.71%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$6.28 -0.04 (-0.63%)

As of 10/2/2026 07:57 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Eliem Therapeutics NASDAQ:ELYM

$10.94 -0.13 (-1.17%)

As of 10/2/2026

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Ocugen NASDAQ:OCGN

$1.02 +0.02 (+2.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.01 -0.01 (-0.49%)

As of 10/2/2026 07:58 PM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Oncolytics Biotech NASDAQ:ONCY

$0.63 -0.01 (-1.59%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.64 +0.01 (+2.22%)

As of 10/2/2026 07:57 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ONCY, EBS, ELYM, and OCGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ONCY, EBS, ELYM, and OCGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ONCY, EBS, ELYM, and OCGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY, EBS, ELYM, and OCGN Company Descriptions

Emergent Biosolutions NYSE:EBS

Eliem Therapeutics NASDAQ:ELYM

Ocugen NASDAQ:OCGN

Oncolytics Biotech NASDAQ:ONCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ONCY, EBS, ELYM, and OCGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ONCY, EBS, ELYM, and OCGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ONCY, EBS, ELYM, and OCGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY, EBS, ELYM, and OCGN Company Descriptions

Emergent Biosolutions NYSE:EBS

Eliem Therapeutics NASDAQ:ELYM

Ocugen NASDAQ:OCGN

Oncolytics Biotech NASDAQ:ONCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools